Navigation Links
Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System

Purpose

In this application note, several different metabolite identification approaches are evaluated for their merits. A comprehensive examination of four Information Dependent Acquisition (IDA) survey modes was performed to illustrate data quality and types of metabolites found. A significant number of metabolites were found with each mode of operation to create a thorough investigation of the metabolites derived from glyburide.

Overview

A common strategy for metabolite analysis consists of using two mass spectrometry (MS) systemsa triple quadrupole MS system to identify metabolites, and a separate ion trap MS system to characterize the metabolites. The sample is split and run on the separate instruments in a sequential manner with the metabolite identification information from the triple quadrupole used to drive the characterization analysis on the 3D ion trap. Alternatively, methods have been proposed that split the HPLC flow into the two separate MS systems in an effort to get the information at the same time. Either way, the two separate systems approaches are not ideal. Triple quadrupole scan modes such as precursor ion and neutral loss provide a very selective method for the identification of structurally similar metabolites even in the presence of major background contaminants from complex biological matrices. With these selective scan modes, conventional triple quadrupoles can effectively identify metabolite candidates for further characterization analysis. Unfortunately, due to their inherent poor MS/MS full scan sensitivity, triple quadrupoles are not ideal tools to acquire MS/MS characterization data on critical low-level metabolites.

Also 3D ion trap systems alone cannot provide complete metabolite investigation. In this single-system approach, a single MS survey scan is commonly followed by a dependent MS/MS scan for structural characterization
'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. TKB1 Cells Identify Receptor Tyrosine Kinase Interacting Proteins
2. Using the DCode System to Identify DNA Sequence Variation for Studies of Population Structure in Marine Organisms
3. A Screen of shRNAs Targeting Tumor Suppressor Genes to Identify Factors Involved in Paclitaxel Sensitivity
4. Confirming gene silencing mechanism by pGFP/GFP22 siRNA co-transfection
5. Confirming RNAi Effects Is Now Easier Than Ever
6. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
7. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
8. Easy preparation of total RNA from cultured cells with TRIzol and Eppendorf Phase Lock Gel
9. Direct Monitoring of Solid-Phase Peptide Synthesis by MALDI-TOF MS
10. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System
11. Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System
Post Your Comments:
Breaking Biology Technology:Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 2Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 3Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 4
Other Biology Technology:Shire's New Product Portfolio Delivers Strong Quarterly Performance 2Shire's New Product Portfolio Delivers Strong Quarterly Performance 3Shire's New Product Portfolio Delivers Strong Quarterly Performance 4Shire's New Product Portfolio Delivers Strong Quarterly Performance 5Shire's New Product Portfolio Delivers Strong Quarterly Performance 6Shire's New Product Portfolio Delivers Strong Quarterly Performance 7Shire's New Product Portfolio Delivers Strong Quarterly Performance 8Shire's New Product Portfolio Delivers Strong Quarterly Performance 9Shire's New Product Portfolio Delivers Strong Quarterly Performance 10Shire's New Product Portfolio Delivers Strong Quarterly Performance 11Shire's New Product Portfolio Delivers Strong Quarterly Performance 12Shire's New Product Portfolio Delivers Strong Quarterly Performance 13Shire's New Product Portfolio Delivers Strong Quarterly Performance 14Shire's New Product Portfolio Delivers Strong Quarterly Performance 15Shire's New Product Portfolio Delivers Strong Quarterly Performance 16Shire's New Product Portfolio Delivers Strong Quarterly Performance 17Shire's New Product Portfolio Delivers Strong Quarterly Performance 18Shire's New Product Portfolio Delivers Strong Quarterly Performance 19Shire's New Product Portfolio Delivers Strong Quarterly Performance 20Shire's New Product Portfolio Delivers Strong Quarterly Performance 21Shire's New Product Portfolio Delivers Strong Quarterly Performance 22Shire's New Product Portfolio Delivers Strong Quarterly Performance 23Shire's New Product Portfolio Delivers Strong Quarterly Performance 24Shire's New Product Portfolio Delivers Strong Quarterly Performance 25Shire's New Product Portfolio Delivers Strong Quarterly Performance 26Shire's New Product Portfolio Delivers Strong Quarterly Performance 27Shire's New Product Portfolio Delivers Strong Quarterly Performance 28Shire's New Product Portfolio Delivers Strong Quarterly Performance 29Shire's New Product Portfolio Delivers Strong Quarterly Performance 30Shire's New Product Portfolio Delivers Strong Quarterly Performance 31Shire's New Product Portfolio Delivers Strong Quarterly Performance 32Shire's New Product Portfolio Delivers Strong Quarterly Performance 33Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference 2Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference 3Sinovac to Participate in Two Upcoming Investor Conferences 2
Breaking Biology News(10 mins):UCLA researchers engineer bacteria to turn carbon dioxide into liquid fuel 2Princeton scientists find way to catalog all that goes wrong in a cancer cell 2Berkeley Lab researchers participate in Homeland Security study of subway airflow 2Lockheed Martin Expands Health IT Business with 24170 Million in New Health 26amp 3B Human Services Contract Awards 60095 1Lockheed Martin Expands Health IT Business with 24170 Million in New Health 26amp 3B Human Services Contract Awards 60095 2Rcadia Medical Imaging Wins 2009 AuntMinnie com Best New Radiology Vendor Award 5701 1Rcadia Medical Imaging Wins 2009 AuntMinnie com Best New Radiology Vendor Award 5701 2Rcadia Medical Imaging Wins 2009 AuntMinnie com Best New Radiology Vendor Award 5701 3New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 1New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 2New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 3New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 4New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 5New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 6New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 7New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 8New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 9New Data Show CIMZIA 28R 29 28certolizumab pegol 29 Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients 5696 10